top of page

Incyte’s Zynyz receives MHRA approval and NICE recommendation for anal cancer

Regulatory approval and NICE guidance introduce a new first-line treatment option for eligible patients with advanced squamous cell carcinoma of the anal canal.

Incyte’s Zynyz receives MHRA approval and NICE recommendation for anal cancer

Incyte Biosciences UK has secured UK marketing authorisation and a NICE recommendation for Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel, introducing the first immunotherapy treatment licensed in the UK for anal cancer.


The treatment is indicated for the first-line treatment of adults with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) who have not previously received systemic chemotherapy for advanced disease.


The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation on 5 November 2026, with its announcement published on 11 November. NICE subsequently published final draft guidance recommending the treatment on 12 November, with eligible patients in England able to access it through the NHS immediately.


The decision is supported by results from the Phase 3 POD1UM-303/InterAACT2 trial, the first positive Phase 3 study of a systemic therapy in this advanced disease setting.


Phase 3 trial demonstrates improved clinical outcomes

The POD1UM-303/InterAACT2 trial enrolled 308 patients across 70 centres in 12 countries, including 56 patients at ten hospitals in the UK. Participants had metastatic or inoperable locally recurrent SCAC and had not previously received systemic chemotherapy for their advanced disease.


The study evaluated retifanlimab or placebo, each in combination with platinum-based chemotherapy comprising carboplatin and paclitaxel. Its primary endpoint was progression-free survival (PFS), defined as the time from randomisation to disease progression or death from any cause.


Results demonstrated a statistically significant improvement in PFS for patients receiving retifanlimab alongside chemotherapy compared with those receiving chemotherapy alone.

The trial also reported a 25% reduction in the estimated risk of death in the retifanlimab treatment arm. Median overall survival was 32.8 months, compared with 22.2 months in the placebo and chemotherapy arm (hazard ratio 0.75; 95% confidence interval 0.55–1.01).


Dr Sheela Rao, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and Chief Investigator of the POD1UM-303/InterAACT2 trial, said:


“The POD1UM-303/InterAACT2 study was the largest Phase 3 trial to evaluate an immunotherapy in advanced squamous cell anal carcinoma, and the first to report positive results, including reducing risk of death by 25% which is hugely significant.”

She added that the approval represented an important milestone for the anal cancer community, bringing an additional treatment option into clinical practice in an area where options have historically been limited.


Retifanlimab is a humanised monoclonal antibody targeting programmed death receptor-1 (PD-1), an immune checkpoint involved in regulating the body's immune response. By blocking this pathway, the treatment is designed to help the immune system recognise and attack cancer cells.


Addressing an underserved cancer population

Around 1,700 people are diagnosed with anal cancer each year in the UK, with approximately six in ten cases occurring in women. Squamous cell carcinomas account for more than 80% of anal cancer cases, while incidence is projected to increase by around 13% between now and 2038–2040.


Despite its impact, anal cancer remains an area of significant unmet clinical need. Patients can experience substantial physical and psychosocial effects, while a lack of public awareness and understanding of the disease can contribute to stigma and social isolation.

The approval also comes amid renewed policy focus on improving outcomes for people affected by rare cancers. The Government's National Cancer Plan for England, published in February 2026, sets out ambitions to improve the prioritisation of rare cancers and access to treatment.


Michael Anderson, CEO and Co-Founder of anal cancer support group Bottom Line, welcomed the decision, describing it as a significant development for a patient community that has seen limited treatment advances.


David Winterflood, CEO of the Anal Cancer Foundation UK, also highlighted the importance of the approval in bringing greater attention to a cancer that remains poorly understood.


Patient experience highlights the impact of anal cancer

The wider impact of the disease is illustrated by the experience of Michelle, a 46-year-old woman from Essex who was diagnosed with anal cancer in September 2024.


Previously fit and active, Michelle experienced sudden rectal bleeding before being diagnosed and undergoing emergency surgery for a stoma, followed by 28 days of chemoradiotherapy.


Her treatment resulted in significant fatigue, pain and mobility difficulties, while recovery brought additional challenges, including treatment-induced menopause and the psychological impact of being unable to exercise, which had previously been central to her physical and mental wellbeing.


Michelle also highlighted the stigma surrounding anal cancer and the lack of dedicated peer support available to patients navigating the disease.

“There shouldn’t be a stigma against it, but if truth be known, there is,” she said. “Let’s be open and honest about it because the more we talk about it, the less stigma there’s going to be against it.”


Her experience subsequently helped motivate her involvement in establishing The Brave Behinds, a UK-based support group co-founded with Ali to provide practical, peer-to-peer support for people affected by anal and HPV-related cancers.


Since completing treatment, Michelle has gradually returned to an active lifestyle, including completing a half marathon and a triathlon.


NHS access and regional availability

NICE published its recommendation for retifanlimab alongside platinum-based chemotherapy on 12 November 2026. Eligible patients in England can access the treatment through the NHS immediately.


In Wales, the All Wales Medicines Strategy Group typically adopts NICE guidance where available. Incyte also expects the access position in Northern Ireland to be similar to England and Wales, although this is subject to the relevant arrangements. In Scotland, reimbursement decisions are considered separately by the Scottish Medicines Consortium (SMC), with Incyte stating that it will provide an update on the position as appropriate.


The approval represents a new treatment option for eligible patients with advanced anal cancer, supported by Phase 3 clinical evidence in a disease area where systemic treatment advances have historically been limited.

author profile picture

Author

BioFocus Newsroom

bottom of page